Literature DB >> 3165974

[Ofloxacin in the treatment of Pseudomonas aeruginosa infections of the ear].

G Oberascher1, C Karas.   

Abstract

Twenty-three patients suffering from a Pseudomonas infection of the ear were treated with ofloxacin in a prospective study. The type of infection was as follows: external otitis 4, external otitis with furuncle 3, external otitis and otitis media 5, acute exacerbation of chronic otitis media 7, infection of radical mastoidectomy 3, malignant external otitis 1. All patients had previously been unsuccessfully treated elsewhere. The average period of infection was 13.7 days. The patients received 200 mg of ofloxacin (Tarivid) twice daily for 3 weeks. At the same time the ear was cleaned by suction at 2-4 day intervals and a Normison ear strip applied. Twenty patients were completely cured, 2 patients stopped taking ofloxacin early as a result of improved symptoms but their condition subsequently deteriorated. After a further 3 weeks of consistent treatment both of the cases were also cured. Hence only one patient did not respond to our therapy; that is a success rate of 95%. These results are compared with those of our former therapeutic plan in which all patients with resistant Pseudomonas ear infections were treated as in-patients with selected intravenous antibiotics.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3165974

Source DB:  PubMed          Journal:  HNO        ISSN: 0017-6192            Impact factor:   1.284


  3 in total

Review 1.  Ofloxacin. A reappraisal of its antimicrobial activity, pharmacology and therapeutic use.

Authors:  P A Todd; D Faulds
Journal:  Drugs       Date:  1991-11       Impact factor: 9.546

2.  Concentrations of ofloxacin in ear and nasal tissues.

Authors:  P Tolsdorff
Journal:  Eur Arch Otorhinolaryngol       Date:  1993       Impact factor: 2.503

3.  Tissue and serum concentrations of ofloxacin in the ear region following a single daily oral dose of 400 mg.

Authors:  P Tolsdorff
Journal:  Infection       Date:  1993 Jan-Feb       Impact factor: 3.553

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.